New Blood Test to Predict Reaction to Anti-TNF Therapies

Trial Objective

New Blood Test to Predict Reaction to Anti-TNF TherapiesThis study evaluates an investigational blood test called PrismRATM that identifies patients who may not respond well to anti-TNF therapies. By identifying patients who won’t respond to anti-TNF therapies before they start treatment, health care providers will be able to start alternative approved targeted therapies for these patients earlier and, potentially, reach low disease activity (LDA) sooner.


New enrollment for this trial is temporarily paused

Who Can Participate

Age: 18+    Gender: Any Gender

Estimated Time Commitment

4 clinic visits over 6 months

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Megan Rosa

Megan Rosa

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Scipher Medicine, Corp.

Principal Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at